Ocular Therapeutix needed a clean sweep in its expansive Phase III program for a postoperative eye treatment in order to set itself up for a clear shot at an FDA approval. But it didn't get it.
Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb signed a $1.25 billion deal to buy the fledgling biotech in February, but the company's founders aren't resting on their laurels, turning around with immediate plans for a new startup.
High-profile U.K. investor Neil Woodford is putting more chips on the controversial Northwest Biotherapeutics, betting another $40 million on the company as it works through Phase III with a cancer vaccine.
Alkermes unveiled more positive data for a schizophrenia drug the company believes can treat the disease without spurring weight gain, beating a path to late-stage development.
Germany's MorphoSys is moving on after the surprise cancelation of a Celgene partnership spooked investors and battered the company's share price, with CEO Simon Moroney preaching patience for an early-stage cancer candidate.
Novartis and Juno Therapeutics, pioneers in a promising new field of cancer treatment, have reached a settlement in their long-running patent dispute, clearing the way for each to advance rival therapies designed to weaponize the immune system.
Bristol-Myers Squibb is the latest pharma heavyweight to buy into gene therapy's renaissance, signing a deal with uniQure worth as much as $1 billion and getting its hands a novel cardiovascular treatment.
GlaxoSmithKline is setting up a global vaccines hub in Rockville, MD, in the wake of its big asset swap with Novartis. And the move will force hundreds of staffers in Cambridge, MA, and Philadelphia to either look for a relocation package or exit the company.
23andMe, the Silicon Valley maker of personalized gene tests, has picked off another Genentech luminary to help it evolve into a biotech company, recruiting the famed drugmaker's head of bioinformatics.
AstraZeneca's former R&D operations in Delaware, abandoned years ago in the pharma giant's ongoing restructuring and downsizing, are being razed.
French drugmaker Ipsen is the latest global giant turning to the Boston area for a leg up in R&D, cutting the ribbon on a Cambridge research center and breaking it in by signing a deal with Harvard University.
Pharma heavyweight Novartis has stepped in to help bankroll Berkeley, CA-based Caribou Biosciences, one of the upstart leaders in the race to develop the cutting-edge CRISPR-Cas9 gene editing technology.
Looking to gain an edge for its lackluster in-house R&D operations, Sanofi has signed on with Schrödinger to use computational design technology to help guide up to 10 drug discovery programs, promising to pay up to $120 million in milestones for the work.
Index Ventures now has 650 million more euros to invest. The venture group, which has two big teams active on both sides of the Atlantic in life sciences as well as tech, filed documents with the SEC noting that its new Index Ventures Growth III--domiciled in Jersey--is fully sold.
With its stomach-filling particles now in a pivotal study in Europe for obesity, Boston-based Gelesis has thrown its hat into the crowded biotech IPO ring, looking to raise $60 million from an investment community that has yet to lose its appetite for biotech stocks.
In this week's EuroBiotech Report, Cerenis Therapeutics and Ose Pharma both debuted on the Paris stock exchange. And with Sensorion filing the paperwork for a €12 million ($12.9 million) listing, Paris is set move within touching distance of its 2014 IPO haul before the daffodils in the Jardin des Tuileries finish blooming. And more.
The European Medicines Agency (EMA) is preparing to step up its conditional approval initiative to cut the time and data needed to bring new drugs to patients. Having received applications to enter 58 drugs into the program, EMA has selected a treatment based on genes, cells or tissue engineering as the first candidate to advance to the next stage.
AstraZeneca's AZD0530 proved a disappointment as a new drug for solid tumors, but a Yale team says it may prove more effective in a new program for Alzheimer's.
Google's secretive Calico signed yet another partnership with a world-class research outfit, this time divulging some details that could provide clues on how it plans to attack aging.